文献速递淋巴瘤造血干细胞移植与细胞治疗

弥漫大B细胞淋巴瘤患者CAR-T细胞制备失败的危险因素:日本全国性调查

Risk factors for CAR-T cell manufacturing failure among DLBCL patients: A nationwide survey in Japan.
PubMed 文献 · Br J Haematol · 2023-04-25

日本全国性队列研究分析接受tisagenlecleucel生产的弥漫大B细胞淋巴瘤(DLBCL)患者,比较30例制备失败(7.4%)与378例成功患者的临床因素。失败组既往苯达莫司汀治疗比例显著更高,采集时血小板计数和CD4/CD8 T细胞比值显著更低。多因素分析显示重复苯达莫司汀使用且洗脱期短、低血小板计数或低CD4/CD8比值增加制备失败风险。

要点

  • 制备失败组既往苯达莫司汀治疗比例43.3% vs 成功组14.8%(p<0.001)。
  • 采集时血小板计数失败组12.0 vs 成功组17.0×10⁴/μL(p=0.01),CD4/CD8比值0.30 vs 0.56(p<0.01)。
  • 多因素分析:≥6周期苯达莫司汀且洗脱期3-24个月OR 5.52(p=0.013);≥3周期且洗脱期<3个月OR 57.09(p=0.005);低血小板计数OR 0.495每10⁵/μL(p=0.022);CD4/CD8比值<三分之一OR 3.249(p=0.011)。

核心结论

  • 制备失败仍是DLBCL患者CAR-T细胞治疗的障碍。
  • 避免危险因素如无充分洗脱期的重复苯达莫司汀给药及风险适应策略可能有助于优化CAR-T细胞治疗。

研究设计与样本

  • 日本全国性队列研究,分析接受tisagenlecleucel生产的DLBCL患者。
  • 比较30例制备失败(7.4%)与378例成功患者的临床因素。

主要发现

  • 失败组既往苯达莫司汀治疗比例43.3% vs 成功组14.8%(p<0.001)。
  • 失败组采集时血小板计数12.0 vs 成功组17.0×10⁴/μL(p=0.01)。
  • 失败组采集时CD4/CD8 T细胞比值0.30 vs 成功组0.56(p<0.01)。
  • 多因素分析:≥6周期苯达莫司汀且洗脱期3-24个月OR 5.52(p=0.013);≥3周期且洗脱期<3个月OR 57.09(p=0.005);低血小板计数OR 0.495每10⁵/μL(p=0.022);CD4/CD8比值<三分之一OR 3.249(p=0.011)。

临床怎么用

  • 作者认为避免无充分洗脱期的重复苯达莫司汀给药及风险适应策略可能有助于优化DLBCL患者的CAR-T细胞治疗。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

For successful chimeric antigen receptor T (CAR-T) cell therapy, CAR-T cells must be manufactured without failure caused by suboptimal expansion. In order to determine risk factors for CAR-T cell manufacturing failure, we performed a nationwide cohort study in Japan and analysed patients with diffuse large B-cell lymphoma (DLBCL) who underwent tisagenlecleucel production. We compared clinical factors between 30 cases that failed (7.4%) with those that succeeded (n = 378). Among the failures, the proportion of patients previously treated with bendamustine (43.3% vs. 14.8%; p < 0.001) was significantly higher, and their platelet counts (12.0 vs. 17.0 × 104 /μL; p = 0.01) and CD4/CD8 T-cell ratio (0.30 vs. 0.56; p < 0.01) in peripheral blood at apheresis were significantly lower than in the successful group. Multivariate analysis revealed that repeated bendamustine use with short washout periods prior to apheresis (odds ratio [OR], 5.52; p = 0.013 for ≥6 cycles with washout period of 3-24 months; OR, 57.09; p = 0.005 for ≥3 cycles with washout period of <3 months), low platelet counts (OR, 0.495 per 105 /μL; p = 0.022) or low CD4/CD8 ratios (<one third) (OR, 3.249; p = 0.011) in peripheral blood at apheresis increased the risk of manufacturing failure. Manufacturing failure remains an obstacle to CAR-T cell therapy for DLBCL patients. Avoiding risk factors, such as repeated bendamustine administration without sufficient washout, and risk-adapted strategies may help to optimize CAR-T cell therapy for DLBCL patients.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Jo T, Yoshihara S, Okuyama Y, et al. Risk factors for CAR-T cell manufacturing failure among DLBCL patients: A nationwide survey in Japan. Br J Haematol. 2023. PMID: 37096915. doi:10.1111/bjh.18831

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。